RAISIO GROUP INTERIM REPORT 1 JANUARY-31 MARCH 2004<br /><br />Raisio Group's Financial Performance Improved<br /><br />- Raisio Group's turnover for the first quarter was up by 2.3 per<br />cent and totalled EUR 205.6 million (EUR 201.0 million in the<br />first quarter of 2003).<br />- Operating result moved into the black, showing a profit of EUR<br />0.7 million (EUR -6.7 million).<br />- Cash flow from business operations improved significantly<br />compared to the first quarter of 2003.<br />- The divestment of Raisio Chemicals is progressing as planned.<br />- The Group's operative result before taxes for the whole year is<br />expected to show a profit.<br /><br />Key Figures<br /> Q1/2004 Q1/2003 2003<br /><br />Turnover, EUR million 205.6 201.0 860.5<br />Operating result, EUR million 0.7 -6.7 -14.3<br />Result before taxes, EUR million -2.3 -9.2 -27.2<br />Earnings per share, EUR -0.03 -0.06 -0.16<br />Equity ratio, % 31.3 33.7 32.2<br />Cash flow from business operations,<br />EUR million 2.3 -15.6 77.0<br /><br />CEO Rabbe Klemets:<br /><br />“All business sectors showed positive development in the first<br />quarter. The demand for paper chemicals was slightly higher than a<br />year earlier, but the improvement in Raisio Chemicals'<br />profitability could primarily be attributed to the results of the<br />rationalisation programmes carried out last year. The streamlining<br />of Raisio Nutrition's business activities in spring 2003 and the<br />continuing difficulties with margarine sales in Sweden taxed the<br />sector's turnover. Nevertheless, comparable operating result<br />improved. The input Raisio Life Sciences made last year in the<br />European ingredients markets began to pay off through new<br />customers and new product applications in the last quarter of<br />2003. The sector was able to almost double its turnover and make<br />an operating profit.<br /><br />However, what characterised the first quarter most distinctly was<br />the strategy reassessment process, which resulted in the decision<br />to focus the Group's resources on developing the Nutrition and<br />Life Sciences businesses. Therefore, we decided to find a new<br />industrial owner for Raisio Chemicals. Among several potential<br />buyers, Ciba Specialty Chemicals was considered the best<br />alternative from both the financial and the industrial<br />perspective. The enterprise value of EUR 475 million will settle<br />Raisio's debts and will allow it to focus more sharply on its key<br />competence area, well-being.ö<br /><br />RESULTS AND FINANCING<br /><br />Raisio Group recorded a turnover of EUR 205.6 million <br />(EUR 201.0 million) in the first quarter. Raisio Life Sciences and Raisio<br />Chemicals were able to increase their turnover, while Raisio<br />Nutrition's turnover decreased slightly.<br /><br />Using the Q1/2003 exchange rates, turnover was up by 1.8 per cent<br />to EUR 209.3 million. Exchange rate fluctuations did not have a<br />significant impact on the results.<br /><br />Turnover from outside Finland represented 50.7% (53.0%) of the<br />total, or EUR 104.1 million (EUR 106.5 million).<br /><br />Operating result for the first quarter was EUR 0.7 million <br />(EUR -6.7 million). The result before taxes was EUR -2.3 million <br />(EUR -9.2 million).<br /><br />Research and development costs amounted to EUR 5.4 million <br />(EUR 5.8 million).<br /><br />Net financial expenses in the January to March period totalled EUR<br />3.0 million (EUR 2.5 million). Exchange rate losses in the amount<br />of EUR 0.1 million were recorded for the period, compared with<br />gains of EUR 0.5 million a year earlier.<br /><br />Taxes are calculated based on the appropriate tax on the result.<br />The result for the financial period was EUR -4.3 million (EUR -9.3<br />million). The parent company's tax surplus amounts to EUR 8.4<br />million.<br /><br />Cash flow from business operations totalled EUR 2.3 million <br />(EUR -15.6 million) in the first quarter. The Group's gross investments<br />totalled EUR 12.5 million (EUR 8.6 million). The largest single<br />investments involved the construction of paper chemical plants in<br />China. Raisio Nutrition's investments involved launching a<br />margarine factory in Russia and constructing a new production line<br />for the potato processing plant in Vihanti, Finland.<br /><br />The Group's net interest-bearing liabilities were EUR 287.9<br />million (EUR 277.8 million on 31 December 2003) at the end of the<br />period. Equity ratio was 31.3% (32.2% on 31 December 2003) and<br />gearing was 135.6% (127.9% on 31 December 2003). Working capital<br />rose slightly from EUR 110.4 million at the year-end to EUR 113.4<br />million, but was still clearly lower than in the first quarter of<br />2003 (EUR 179.2 million).<br /><br />BUSINESS SECTORS<br /><br />Raisio Chemicals<br /><br />The turnover for Raisio Chemicals was up by 3.3% to EUR 106.5<br />million (EUR 103.2 million). A challenging market situation<br />persisted, although there were signs of recovery in the demand for<br />latex binders in Europe. Customer deliveries from the latex and<br />specialty chemicals plants in China started.<br /><br />Raisio Chemicals Turnover by Business Area, EUR million<br /><br /> Q1/2004 Q1/2003 2003<br /><br />Latices 55.9 47.4 207.7<br />Specialty chemicals 28.1 33.4 125.0<br />Starches 22.5 22.4 89.6<br />Total 106.5 103.2 422.3<br /><br />The results of the rationalisation and efficiency-boosting<br />measures initiated last year reflected on the profitability of<br />Raisio Chemicals: operating result rose to EUR 1.9 million (EUR -<br />3.2 million). The latex and starch binder business areas performed<br />well. Meanwhile, the profitability of the specialty chemicals<br />business was on a par with the previous year.<br /><br />Future Printing Center, an associated company of Raisio Chemicals,<br />launched activities in Raisio at the beginning of 2004.<br /><br />Raisio Nutrition<br /><br />Raisio Nutrition posted a turnover of EUR 91.1 million (EUR 94.6<br />million). The ice cream and almond paste businesses sold in the<br />spring of 2003 as well as the discontinuation of industrial<br />margarine production in Sweden taxed the turnover of the food<br />business area. Margarine sales volumes continued to fall in<br />Sweden. Turnover generated by the feeds and malt business areas<br />remained on the Q1/2003 level.<br /><br />Raisio Nutrition Turnover by Business Area and Business, EUR<br />million<br /><br /> Q1/2004 Q1/2003 2003<br /><br />Food 53.0 57.0 232.2<br /> Margarine 29.1 31.9 130.8<br /> Milling 18.0 19.2 75.3<br /> Food Potato 4.9 4.8 21.2<br /> Others 3.9 3.2 14.4<br /> Internal sales in Food -2.8 -2.0 -9.5<br />Animal Feeds 36.4 36.1 163.8<br />Malt 3.0 2.8 26.4<br />Grain Starch 3.9 3.5 15.0<br />Internal sales -5.3 -4.7 -19.5<br />Total 91.1 94.6 417.9<br /><br />Raisio Nutrition was able to boost its operative results.<br />Disclosed operating result was on a par with Q1/2003 at EUR -1.5<br />million (EUR -1.4 million). The Q1/2003 result includes a sales<br />profit of EUR 1.2 million from the divestment of the ice cream<br />business. The rationalisation programme launched in 2003 had, so<br />far, only a partial impact on the result.<br /><br />Favourable development in the margarine business in Finland and in<br />Poland helped improve the operating result, as did the better<br />performance of the milling business. Result for the animal feeds<br />business was hampered by low pressing margins from the oil milling<br />business.<br /><br />Losses suffered in the Swedish margarine market also strained the<br />sector's financial performance. The strategic and operative<br />reassessment of the Swedish operations is under way. In March,<br />Raisio's last remaining margarine production stage in Sweden was<br />wound up, and the property maintenance services were outsourced.<br />Sales of Raisio's own margarine brands to the Swedish retail trade<br />are now handled through Cerealia Foods' sales network. Further<br />additional decisions will be made by autumn. The Swedish<br />operations carry goodwill of EUR 21.5 million which may include a<br />need for a significant write-down.<br /><br />Raisio Nutrition's margarine production plant in Istra, near<br />Moscow, came online in January. Besides Poland, Russia represents<br />one of the key future growth areas for Raisio Nutrition. The Istra<br />plant and the Russian sales organisation employ approximately 100<br />people in total.<br /><br />Raisio Nutrition and Lännen Tehtaat plan to join sales forces in<br />the catering sector and provide these services through a 50/50<br />owned sales company, Ateriamestarit Oy. The application is still<br />being processed by the Finnish Competition Authority.<br /><br />The Finnish Food and Drink Industries' Federation awarded Raisio<br />Nutrition the “Finnish Food Product of the Yearö award in 2004 in<br />the retail trade grain product series for its multigrain cereal<br />and bran mixture with linseed (Sydänystävä Pellavainen Monivilja).<br />The Beneviva Omega3 light margarine also made it to the finals.<br />Thanks to the Camelina oil used in its production, this margarine<br />contains a significant amount of fatty acids that are essential<br />for humans. The success of these products is an indication of<br />Raisio Nutrition's expertise in the grain and vegetable oil<br />segments.<br /><br />Raisio Life Sciences<br /><br />The turnover for Raisio Life Sciences grew by 88.7% and amounted<br />to EUR 11.8 million (EUR 6.3 million). In addition to the in April<br />2003 acquired food diagnostics company Diffchamb, good development<br />in the ingredient business helped fuel the growth of turnover. The<br />determined inputs made in the European ingredients market last<br />year are beginning to bear fruit.<br /><br />One particularly successful product application is the yoghurt<br />drink sold in small bottles. This product is currently sold in<br />nine European countries. Furthermore, the first quarter saw the<br />launch of milk containing the Benecol ingredient in Spain, a<br />Benecol light spread in Greece and a Benecol yoghurt drink in<br />Finland.<br /><br />Raisio Life Sciences Turnover by Business Area, EUR million<br /><br /> Q1/2004 Q1/2003 2003<br /><br />Ingredients 9.8 6.3 27.0<br />Diagnostics 2.0 - 7.0<br />Total 11.8 6.3 34.0<br /><br />Operating result rose to EUR 0.6 million (EUR -1.6 million) thanks<br />to increased sales volumes and a tight cost-cutting regime<br />implemented in both business areas.<br /><br />PERSONNEL AND ADMINISTRATION<br /><br />Raisio Group employed 2,718 personnel on 31 March 2004 (2,735 on<br />31 December 2003), 47% of whom worked outside Finland (45% on 31<br />December 2003). The number of personnel increased as a result of<br />the launch of Raisio Chemicals' new production plants in China,<br />and the launch of Raisio Nutrition's margarine production in<br />Russia. Meanwhile, the rationalisation programmes and the<br />discontinuation of margarine production in Sweden reduced the<br />number of personnel.<br /><br />At the end of March, Raisio Chemicals employed 1,149 people,<br />Raisio Nutrition 1,329 and Raisio Life Sciences 187.<br /><br />Mr Vesa Lammela, Chairman of the Supervisory Board, resigned from<br />his position after the Annual General Meeting held on 26 March<br />2004. Mr Ola Rosendahl, Vice Chairman, assumed his position for<br />the time being.<br /><br />DECISIONS MADE AT THE ANNUAL GENERAL MEETING<br /><br />Raisio Group plc's Annual General Meeting held on 26 March 2004<br />approved the financial statements for 2003 and discharged those<br />accountable from liability, and decided that a dividend of EUR<br />0.01 per share shall be paid. The dividend was paid on 7 April<br />2004.<br /><br />The Board of Directors was authorised, for one year from the<br />Annual General Meeting, to make a decision to increase the share<br />capital. The maximum number of new shares to be subscribed under<br />the authorisation is 20,000,000; however, the maximum number of<br />restricted shares to be subscribed shall be 5,000,000. So far, the<br />Board has not used its authorisation.<br /><br />A decision was also made to reduce the number of Supervisory Board<br />members to 25, effective as of the beginning of 2005. The<br />following members due to resign were re-elected to the Supervisory<br />Board from 2005 to 2007: Juhani Enkovaara, Erkki S. Koskinen, Hans<br />Langh, Johan Laurén, Asko Leinonen and Yrjö Ojaniemi.<br /><br />Johan Kronberg and Mika Kaarisalo, authorised public accountants,<br />were elected regular auditors for the financial year 2005. The<br />accounting firm of PricewaterhouseCoopers Oy and Kalle Laaksonen,<br />authorised public accountant, were elected deputy auditors.<br /><br />SHARES AND SHAREHOLDERS<br /><br />The trading volume of Raisio Group plc's free shares grew<br />significantly in the first quarter. The number of free shares<br />traded on the Helsinki Exchanges between January and March<br />totalled 46.6 million (11.6 million in Q1/2003). The value of<br />share trading was EUR 65.9 million and the average share price was<br />EUR 1.42. The closing price on 31 March 2004 was EUR 1.54. The<br />price of the Series V share rose by 22% from the beginning of the<br />year.<br /><br />A total of 456,621 restricted shares were traded in the January to<br />March period (63,886). The value of share trading was EUR 683,524<br />and the average share price was EUR 1.50. The closing price on 31<br />March 2004 was EUR 1.52. The price of the Series K share rose by<br />23% from the beginning of the year.<br /><br />On 31 March 2004, Raisio Group had 45,996 registered shareholders.<br />Of all shares, 7.7% was in foreign holding (5.8% on 31 December<br />2003) with the corresponding value for free shares being 9.7%<br />(7.4% on 31 December 2003).<br /><br />The subscription period for the 1998-2003 option programme ended<br />on 30 January 2004. No shares were subscribed under this<br />programme.<br /><br />ADOPTION OF THE IFRS ACCOUNTING STANDARDS<br /><br />Preparation for the adoption of the IFRS standard compliant<br />accounting system has progressed as planned. Raisio Group will<br />adopt IFRS compliant accounting methods in 2005. IFRS compliant<br />figures for 2004 will be published in the spring of 2005.<br /><br />THE DIVESTMENT OF RAISIO CHEMICALS<br /><br />In March 2004, Raisio Group and the Swiss Ciba Specialty Chemicals<br />signed an agreement regarding the sale of Raisio Chemicals.<br /><br />The enterprise value of the sale is EUR 475 million. The sale<br />price consists of a cash payment and the transfer of debts. The<br />sale price will generate approximately EUR 200 million in pre-tax<br />sales profit. The sale of Raisio Chemicals will raise Raisio<br />Group's equity ratio to approximately 80%, assuming all interest-<br />bearing debt would be repaid. Finalising the deal requires the<br />approval of the competition and merger control authorities. All<br />the necessary filing has been made. The final closing date depends<br />on the length of the regulatory review, but it is currently<br />expected to take place in the second or the third quarter of 2004<br /><br />STRATEGY PROCESS<br /><br />The new Group strategy will be built on special expertise in well-<br />being, which is at the heart of Raisio's activities in the food<br />and the functional food ingredients, animal feeds and food<br />diagnostics.<br /><br />One of the cornerstones of the strategy, which is currently being<br />prepared, is to accelerate organic growth. Measures taken to<br />pursue organic growth include stronger focus on research and<br />development, which will allow Raisio to renew the product<br />portfolio. By expediting research and development, Raisio can<br />expand the range of plant-based products and launch new, tasty and<br />healthy foods and animal feeds, as well as functional food<br />ingredients. For the fast growing food diagnostics markets rapid<br />testing methods will be developed.<br /><br />To support its objective to bolster R&D activities, Raisio has<br />decided to set up research centres in order to promote food and<br />food diagnostics development. Raisio's new strategic nutrition<br />research unit will be located at the Viikki campus in Helsinki.<br />Strong focus will be placed on product development and quality<br />assurance in the production locations. A food diagnostics<br />research centre will start its operations in Turku Sciences Park<br />in May.<br /><br />Russia and Poland provide interesting growth potential, and<br />networking with other players in the field is already under way in<br />the Baltic Sea region. Ingredient and diagnostic businesses are<br />expected to drive Raisio's global expansion and rapid growth.<br /><br />The strategy will be published during the summer.<br /><br />OUTLOOK<br /><br />The implemented rationalisation and efficiency-boosting measures<br />will help trim costs, thereby allowing both Raisio Chemicals and<br />Raisio Nutrition to improve their financial performance despite<br />the challenging business environment. Raisio Life Sciences is<br />expected to sustain good growth and improve its profitability also<br />in the following quarters. Raisio Group's operative result before<br />taxes for the whole year is expected to show a profit.<br /><br />The divestment of Raisio Chemicals should be finalised in the<br />second or third quarter. The sale price of EUR 475 million will<br />make Raisio a debt-free company. The sales profit will increase<br />the operating profit by some EUR 200 million and profit after<br />taxes by some EUR 140 million.<br /><br />Raisio, 4 May 2004<br /><br />Raisio Group plc<br />Board of Directors<br /><br />Further information:<br />Taru Narvanmaa, Executive Vice President, Communications and<br />Investor Relations, tel. +358 50 590 9398<br />Antti Salminen, Chief Financial Officer, tel. +358 40 535 1216<br /><br />Raisio Group plc, P.O.Box 101, FI-21201 Raisio, Finland<br />tel. +358 2 443 2111, www.raisiogroup.com<br /><br />Press- and analyst meetings will be held on 4 May 2004 at 11.30 in<br />Raisio and at 15.00 in Helsinki. English conference call will be<br />held at 16.30 Finnish time.<br /><br />The figures in this interim report are not audited.<br /><br />CONSOLIDATED INCOME STATEMENT<br />(EURm) 1-3/2004 1-3/2003 2003<br /><br />Turnover 205.6 201.0 860.5<br /><br /> Income and expenses from<br /> business operations -192.2 -194.5 -814.5<br /> Depreciation of goodwill -1.3 -1.2 -5.1<br /> Other depreciation and write-downs -11.1 -11.9 -54.8<br /> Share of associated companies'<br /> results -0.2 -0.1 -0.3<br />Operating result 0.7 -6.7 -14.3<br /> % of turnover 0.3 -3.3 -1.7<br /><br /> Financial income 0.8 1.6 4.1<br /> Financial expenses -3.8 -4.1 -17.0<br /><br />Result before extraordinary items<br />and taxes -2.3 -9.2 -27.2<br /> % of turnover -1.1 -4.6 -3.2<br /><br /> Extraordinary items 0.0 0.0 0.0<br /><br /> Result before taxes -2.3 -9.2 -27.2<br /> % of turnover -1.1 -4.6 -3.2<br /><br /> Income taxes -2.0 0.0 1.4<br /> Minority interest 0.0 -0.1 -0.9<br /><br />Consolidated result for the period -4.3 -9.3 -26.7<br /> % of turnover -2.1 -4.6 -3.1<br /><br />CONSOLIDATED BALANCE SHEET<br />(EURm) 31.3.2004 31.3.2003 31.12.2003<br /><br />Non-current assets<br /> Intangible assets 23.6 26.9 23.4<br /> Goodwill 63.9* 56.4 65.3<br /> Tangible assets 280.0 282.3 277.2<br /> Investments 12.5 13.3 12.6<br /><br />Current assets<br /> Inventories 119.2 142.0 117.7<br /> Deferred tax assets 20.5 12.7 20.3<br /> Accounts receivable 89.7 118.0 86.8<br /> Other receivables 39.6 42.5 37.1<br /> Securities under financial assets 11.6 13.0 14.1<br /> Cash in hand and at banks 18.5 9.8 20.5<br /><br />Assets 679.1 716.9 675.0<br /><br /> Share capital 27.8 27.8 27.8<br /> Other shareholders' equity 161.8 190.4 166.2<br /> Minority interest 22.8 23.3 23.2<br /> Deferred tax liability 22.0 20.5 22.0<br /> Non-current liabilities 237.7* 247.8 235.0<br /> Accounts payable 67.6 60.4 75.2<br /> Other current liabilities 139,5 146.7 125.5<br /><br />Liabilities 679.1 716.9 675.0<br /><br />Raisio Chemicals EUR 21.8 million, Raisio Nutrition EUR 25,2<br />million, Raisio Life Sciences EUR 16,8 million.<br /><br />*A total of USD 154 million had been withdrawn under the Group's<br />syndicated loan facility by 31 March 2004. The total credit limit<br />is USD 190 million, and the key covenant is an equity ratio of at<br />least 30%.<br /><br />CONSOLIDATED SOURCE AND APPLICATION OF FUNDS<br />(EURm)<br /> 1-3/2004 1-3/2003 31.12.2003<br /><br />Cash flow before change in<br />working capital 13.6 6.4 44.4<br />Change in working capital -5.9 -18.3 50.7<br />Financial items and taxes -5.3 -3.7 -18.2<br />Cash flow from business operations 2.3 -15.6 77.0<br /><br />Investments -12.2 -9.5 -65.8<br />Proceeds from sales of fixed assets 0.5 1.9 3.6<br />Cash flow from investments -11.6 -7.6 -62.2<br /><br />Change in non-current loans 1.0 -0.7 -18.1<br />Change in current liabilities 3.4 4.3 -1.0<br />Change in loan receivables -0.1 0.0 0.1<br />Dividend paid -0.2 0.0 -3.5<br />Cash flow from financial operations 4.2 3.7 -22.6<br /><br />Unallocated items 0.6 0.2 0.3<br /><br />Change in liquid funds -4.6 -19.4 -7.5<br /><br />Liquid funds at beginning of period 34.6 42.2 42.2<br />Liquid funds at end of period 30.1 22.8 34.6<br /><br />FINANCIAL INDICATORS<br /> 31.3.2004 31.3.2003 31.12.2003<br /><br />Return on equity, ROE, % -8.0 -14.7 -10.9<br />Return on investment, ROI, % 1.1 -3.5 -1.8<br /><br />Interest-bearing liabilities<br />at end of period, EURm 318.0 334,8 312.5<br />Gross investments, EURm 12.5 8.6 63.7<br /> % of turnover 6.1 4.3 7.4<br />R & D expenditure, EURm 5.4 5.8 21.1<br /> % of turnover 2.6 2.9 2.5<br />Personnel average 2,719 2,747 2,822<br />Equity ratio, % 31.3 33.7 32.2<br />Gearing, % 135.6 125.3 127.9<br />Earnings/share, EUR -0.03 -0.06 -0.16<br />Cash flow from operations/share, EUR 0.01 -0.09 0.47<br />Equity/share, EUR 1.15 1.32 1.17<br />Average number of shares during<br />the period, in 1000s<br /> Free shares 130,097 129,765 129,768<br /> Restricted shares 35,052 35,384 35,381<br /> Total 165,149 165,149 165,149<br />Market capitalization of shares at<br />end of period, EURm<br /> Free shares 201.0 111.6 160.9<br /> Restricted shares 52.6 42.5 44.6<br /> Total 253.6 154.1 205.5<br /><br />CONTINGENT LIABILITIES<br />(EURm) 31.3.2004 31.3.2003 31.12.2003<br /><br />Assets given as security<br /> For the company<br /> Mortgages on real estate 72.6 61.4 72.4<br /> Securities pledged 4.1 0.0 4.0<br /> Corporate mortgages 46.9 49.0 53.1<br /><br />Contingent off-balance-sheet<br />liabilities<br /> Leasing liabilities<br /> Amounts outstanding on leasing contracts<br /> Falling due during 2004 4.1 3.4 4.7<br /> Falling due later 7.9 6.7 4.9<br /> Contingent liabilities for the<br /> Group companies<br /> Guarantees 1.0 6.0 1.0<br /> Contingent liabilities for the Company 4.8 13.3 7.0<br /> Contingent liabilities for<br /> associated companies<br /> Guarantees 0.0 15.5 0.0<br /> Contingent liabilities for others<br /> Guarantees 1.1 1.1 0.4<br /> Other liabilities 5.0 0.0 5.0<br /> Liabilities arising from<br /> derivative contracts<br /> Raw material futures: market value -1.0 -0.3 -0.5<br /> Raw material futures:<br /> value of underlying instruments 14.0 13.0 11.3<br /> Forward electricity contracts:<br /> market value 0.2 0.0<br /> Forward electricity contracts:<br /> value of underlying instruments 4.1 2.6<br /> Currency forward contracts:<br /> market value 1.5 -0.1 2.1<br /> Currency forward contracts:<br /> value of underlying instruments) 61.9 18.6 53.0<br /> Interest-rate swaps: market value -1.7 0.2 -1.5<br /> Interest-rate swaps:<br /> value of underlying instruments 80.0 60.0 80.0<br /><br />) Some equity hedging of foreign subsidiaries was adopted during<br />the review period, resulting in an appreciable increase in the<br />total value of underlying instrument for currency forward<br />contracts.<br /><br />CONSOLIDATED TURNOVER BY BUSINESS SECTORS<br />(EURm) 1-3/2004 1-3/2003 2003<br /><br />Raisio Chemicals 106.5 103.2 422.3<br />Raisio Nutrition 91.1 94.6 417.9<br />Raisio Life Sciences 11.8 6.3 34.0<br />Interdivisional -3.9 -3.0 -13.8<br /><br />Turnover, total 205.6 201.0 860.5<br /><br />CONSOLIDATED TURNOVER BY MARKET AREA<br />(EURm) % of % of % of<br /> 1-3/ turn- 1-3/ turn- turn-<br /> 2004 over 2003 over 2003 over<br /><br />Finland 101.4 49.3 94.5 47.0 412.0 47.9<br />Scandinavia 11.4 5.5 18.7 9.3 66.5 7.7<br />Europe (excl. Finland<br />and Scandinavia) 68.9 33.5 62.5 31.1 278.2 32.3<br />The Americas 11.2 5.5 11.1 5.5 47.4 5.5<br />Asia 12.1 5.9 14.1 7.0 54.6 6.3<br />Other 0.6 0.3 0.1 0.1 1.9 0.2<br /><br />Total 205.6 100.0 201.0 100.0 860.5 100.0<br /><br />CONSOLIDATED OPERATING RESULT BY BUSINESS SECTORS<br />(EURm) 1-3/2004 1-3/2003 2003<br /><br />Raisio Chemicals 1,9 -3.2 1.9<br />Raisio Nutrition -1,5 -1.4 -11.7<br />Raisio Life Sciences 0,6 -1.6 -5.4<br />Others -0,3 -0,6 1.0<br /><br />Operating result, total 0,7 -6.7 -14.3<br /><br />QUARTERLY PERFORMANCE)<br />(EURm) 1-3/ 4-6/ 7-9/ 10-12/ 1-3/<br /> 2003 2003 2003 2003 2004<br />Consolidated turnover<br />Raisio Chemicals 103.2 109.4 105.4 104.3 106.5<br />Raisio Nutrition 94.6 110.4 108.5 104.4 91,1<br />Raisio Life Sciences 6.3 8.3 8.5 11.0 11.8<br />Interdivisional -3.0 -3.3 -3.8 -3.6 -3.9<br /><br />Turnover, total 201.0 224.8 218.7 216.1 205.6<br /><br />Consolidated operating result<br />Raisio Chemicals -3.2 -0.1 2.9 2.2 1.9<br />Raisio Nutrition -1.4 -2.4 1.3 -9.2 -1.5<br />Raisio Life Sciences -1.6 -1.7 -2.0 -0.2 0.6<br />Others -0.6 0.5 1.0 0.1 -0.3<br />Operating result, total -6.7 -3.7 3.2 -7.1 0.7<br /> Financial items -2.5 -2.5 -4.2 -3.7 -3.0<br />Result before extraordinary<br />items and taxes -9.2 -6.3 -1.0 -10.8 -2.3<br /> Extraordinary items 0.0 0.0 0.0 0.0 0.0<br />Result before taxes -9.2 -6.3 -1.0 -10.8 -2.3<br /> Income taxes 0.0 0.2 -1.0 2.2 -2.0<br /> Minority interest -0.1 -0.2 -0.4 -0.2 0.0<br />Consolidated result for the period<br /> -9.3 -6.2 -2.4 -8.8 -4.3<br />